Emulate, Inc. Appoints Jim Corbett as Chief Executive Officer and Martin Madaus, PhD, as Executive Chairman
Company Builds Leadership Team for Next Stage of Growth with Expanded Commercialization of Organs-on-Chips Product Suite
BOSTON, Mass. – March 19, 2020 – Emulate, Inc., today announced that Jim Corbett has been appointed as Chief Executive Officer and Martin Madaus, Ph.D., has been appointed Executive Chairman of the company’s Board of Directors. These life science leaders join Emulate as the company scales the adoption of its industry-leading Organs-on-Chips product suite that allows researchers to predict human response better than conventional cell culture and animal-based experimental testing.
As CEO of Emulate, Jim Corbett joins the company with more than 25 years of experience in commercial strategy for healthcare and life sciences. Mr. Corbett most recently served as Executive Vice President and President of Discovery & Analytical Solutions at PerkinElmer, a division with 4,000 employees that he led to consecutive years of commercial growth and profitability, as well as promoting product development with the launch of 14 new platforms. He succeeds Emulate’s founding CEO, James Coon, who led the company through its early stage, secured funding from a premier syndicate of investors, and guided the launch of the company’s first products.
As Executive Chairman of Emulate, Martin Madaus brings more than 25 years of experience in the diagnostics and life science industries with a track record for driving company growth and value creation. Dr. Madaus’ most recent roles leading companies with healthcare and life sciences technologies include Chairman and CEO of Ortho Clinical Diagnostics, Chairman and CEO of Quanterix Corporation, Chairman, President and CEO of Millipore Corp, and President and CEO of Roche Diagnostics Corporation.
“Emulate has reached an exciting inflection point for its next stage of growth with the most comprehensive and robust product suite for putting Organs-on-Chips technology in the hands of researchers in drug development and other industries worldwide. Emulate’s platform is already used by 10 of the top 25 pharmaceutical companies, and we plan to continue momentum to gain adoption for our products at all of the top pharmaceutical companies,” said Dr. Madaus. “I also want to acknowledge and thank James Coon for his many contributions and his entrepreneurial success leading Emulate through its early stages of growth and the development of its first commercial products.”
In support of Emulate’s plans for growth and commercialization, the company has continued to build its financial resources and infrastructure. The company secured additional financing from existing investors, including Founders Fund, Cedars-Sinai Medical Center, NanoDimension, ALS Investment Fund, and from new investors including Northpond Ventures and Blue Ivy Ventures. The financing round was led by Northpond Ventures, a leading science, medical, and technology-driven venture capital firm. Northpond’s Sharon Kedar, Co-Founder and Partner at the firm, has joined Emulate’s Board of Directors.
Emulate’s growth plans include expanding the commercialization of its Zoë® lab-ready instrumentation and three commercially available chips: Liver-Chip, Kidney-Chip, and Intestine-Chip. In addition, the company will continue to invest in R&D to support new product development and new applications in key areas of biology and disease, and Dr. Geraldine A. Hamilton, President and Chief Scientific Officer, will continue to oversee and evolve the scientific activities that underlie Emulate’s technology.
“I am excited to join Emulate at this time of enormous opportunity as we expand the team and ramp up the company’s commercial capabilities to realize the potential of Organs-on-Chips technology to impact human health,” said Mr. Corbett. “There is an incredibly strong foundation of scientific excellence, robust product development, and an outstanding team at Emulate that provides a springboard for us to grow the adoption and impact of our products as we look ahead to Emulate’s future.”
About Jim Corbett